✦ LIBER ✦

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

✍ Scribed by Yong Sang Hong; Young Suk Park; Ho Yeong Lim; Jeeyun Lee; Tae Won Kim; Kyu-pyo Kim; Sun Young Kim; Ji Yeon Baek; Jee Hyun Kim; Keun-Wook Lee; Ik-Joo Chung; Sang-Hee Cho; Kyung Hee Lee; Sang Joon Shin; Hye Jin Kang; Dong Bok Shin; Sook Jung Jo; Jae Won Lee

Book ID: 119608998
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 200 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70363-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Leucovorin, fluorouracil, and oxaliplati

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

✍ Yamada, Yasuhide; Takahari, Daisuke; Matsumoto, Hiroshi; Baba, Hideo; Nakamura, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 438 KB

Capecitabine plus oxaliplatin (xelox) ve

Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: A GOAM phase II randomised study (FOCA trial)

✍ Andrea Angelo Martoni; Carmine Pinto; Francesca Di Fabio; Giorgio Lelli; Fabiola 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 176 KB

Phase II study of capecitabine plus oxal

Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer

✍ Yu Hong Li; Hui Yan Luo; Feng Hua Wang; Zhi Qiang Wang; Miao Zhen Qiu; Yan Xia S 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 234 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow